Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders. Chairman and Chief Executive

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $...

It was Griffin's biggest add for Citadel last quarter.

These companies pay durable and growing dividends.

Rising rates can expose dividend traps, but this Dividend King is built to keep paying.

The market's warning signs are driving me to shift my portfolio towards high-quality holdings.

These companies have a long history of dividend growth.

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

A super-high yield isn't everything.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Abbott has a low-risk profile with significant upside potential.

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

It's as stable and consistent as you'd hope from a dividend ETF.

It would be hard for investors to replicate the company's return over the past decade.

These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades.

Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.

They have a knack for increasing their dividends even when facing challenges.

Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.

Long-term holders of the Schwab U.S. Dividend Equity ETF have seen their yield on cost gradually rise.

It is certainly a good Dividend King to buy in September.

Given what's going on in the world and in the market, perhaps it's natural that SCHD is surging.